Nuo Therapeutics CEO buys 8,773 shares

Nuo Therapeutics, Inc. (AURX) reported that CEO/CFO David Emerson Jorden purchased Common Stock in two open-market transactions.

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. (AURX) reported that CEO/CFO David Emerson Jorden purchased Common Stock in two open-market transactions. On 2026-08-28, he bought 7,984 shares at a weighted average price of $1.089 per share, from $1.08–$1.10. On 2026-08-27, he purchased 789 shares at $1.07 per share. The filing’s Rule 10b5-1 checkbox is not marked as being under a trading plan.

Insider Trade Summary

Net Buyer: 8,773 shares

Net Buy 2 txns

Insider JORDEN DAVID EMERSON

Role CEO/CFO

Bought 8,773 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	7,984	$1.089	$9K
Purchase	Common Stock	789	$1.07	$844.23

Holdings After Transaction: Common Stock — 2,070,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

Key Figures

Shares purchased on 2026-08-28: 7,984 shares of Common Stock Weighted average price on 2026-08-28: $1.089 per share Price range on 2026-08-28: $1.08–$1.10 per share +3 more

6 metrics

Shares purchased on 2026-08-28 7,984 shares of Common Stock Open-market purchase by CEO/CFO David Emerson Jorden on 2026-08-28

Weighted average price on 2026-08-28 $1.089 per share Shares purchased in multiple transactions at prices from $1.08 to $1.10

Price range on 2026-08-28 $1.08–$1.10 per share Range of prices for the 7,984 shares purchased on 2026-08-28

Shares purchased on 2026-08-27 789 shares of Common Stock Open-market purchase by CEO/CFO David Emerson Jorden on 2026-08-27

Purchase price on 2026-08-27 $1.07 per share Price paid for 789 shares bought on 2026-08-27

Total shares purchased in filing 8,773 shares Sum of both reported purchases in this Form 4/A

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description": "Purchase in open market or private transaction""

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not marked as being under a trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AURX CEO/CFO David Emerson Jorden report in this Form 4/A?

He reported two open-market purchases of Nuo Therapeutics, Inc. Common Stock: 7,984 shares on 2026-08-28 at a weighted average price of $1.089, and 789 shares on 2026-08-27 at $1.07 per share.

How many AURX shares did the CEO/CFO buy in total in this filing?

Across both reported transactions, the CEO/CFO bought a total of 8,773 shares of Nuo Therapeutics, Inc. Common Stock, consisting of 7,984 shares purchased on 2026-08-28 and 789 shares purchased on 2026-08-27.

What prices did the AURX insider pay for the purchased shares?

For 7,984 shares bought on 2026-08-28, the weighted average price was $1.089 per share, with individual trades between $1.08 and $1.10. For 789 shares bought on 2026-08-27, the reported price was $1.07 per share.

Were the AURX insider purchases made under a Rule 10b5-1 trading plan?

No. The document-level Rule 10b5-1 checkbox is not checked, and there is no footnote stating that these purchases were made pursuant to a pre-arranged trading plan.

What type of security did the AURX insider acquire in these transactions?

In both transactions, the reporting person acquired Common Stock of Nuo Therapeutics, Inc., in open-market or private purchase transactions as indicated by transaction code P and the transaction description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 10:29 AM EDT Accepted by SEC EDGAR 08/31/2026 - 10:29 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JORDEN DAVID EMERSON

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO/CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/29/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2026		P		789	A	$1.07	2,062,016	D
Common Stock	08/28/2026		P		7,984	A	$1.089(1)	2,070,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.

	/s/ David Jorden	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)